With a dynamic and wide-ranging litigation practice, Alisha Nanda stands at the forefront of complex civil litigation and high-stakes regulatory matters, representing major corporations across the nation. With more than two decades of experience, she delivers decisive results for her clients across diverse, complex disputes in state and federal courts, as well as before the U.S. Securities and Exchange Commission (SEC) and state securities regulators.
Nanda is highly regarded for her experience in securities litigation, regulatory investigations, insurance and financial services disputes, and other complex commercial actions. Her work spans an array of industries — including aviation, insurance, health care, life sciences and financial services — reflecting the wide-ranging needs of her clients and her ability to prevail in their most challenging matters.
Lawdragon Honors
| Honor | Year | Practice |
|---|---|---|
| The 2026 Lawdragon 500 Leading Global Investigations Lawyers | 2026 | Litigation, Investigations, Regulatory, Securities |
| The 2026 Lawdragon 500 Leading Litigators in America | 2026 | Securities Litigation, Financial, Insurance |
| The 2025 Lawdragon 500 Leading Litigators in America | 2025 | Securities Litigation, Financial, Insurance |
Nanda is frequently called upon to provide high-level counsel to company executives and boards, offering real-time analysis and guidance on litigation risk, disclosure matters and other issues that inform critical business decisions, allowing clients to proactively manage potential challenges. Whether advising during a crisis or other matter, Nanda aligns legal strategy with business objectives to help clients navigate the challenging legal and regulatory landscapes.
Nanda’s experience includes representing:
Life Sciences, Health Care and Technology
- a pharmaceutical company in securing the dismissal of a putative securities class action following the FDA’s disclosure of safety events concerning an approved drug, which was subsequently affirmed by the U.S. Court of Appeals for the Second Circuit
- a pharmaceutical company in securing the dismissal of a putative securities class action concerning cash projections and the board’s evaluation of strategic alternatives
- a robotics company in securing the dismissal of a putative securities class action concerning the impact of tariffs and competition
- public companies in successfully resolving SEC and U.S. Department of Justice (DOJ) investigations in the pharmaceutical, medical device and technology sectors
Aviation
- an association of major airline carriers in prevailing on federal preemption claims after a two-week federal court trial, which resulted in Massachusetts being enjoined from enforcing certain laws and regulations against the airline industry
- major U.S. airlines and three associations of airline carriers in successfully challenging, in the U.S. Court of Appeals for the Fifth Circuit, a Department of Transportation rule dictating how airlines communicated with customers about ancillary fees; the victory followed earlier success in obtaining a stay of the rule pending appeal
Financial Services
- companies in various regulatory investigations concerning, for example, purported trading improprieties, financial metrics, accounting issues, suspicious activity reporting under the Bank Secrecy Act and other compliance matters
- an investment bank in a class action involving antitrust claims concerning leveraged buyout transactions, which resulted in the dismissal of all claims on summary judgment
Insurance
- a mutual life insurance company in a class action challenging the company’s calculation of the amount of surplus it may retain under state law
- an insurance company in dismissing a purported class action alleging that the company breached its contractual duties to variable annuity and variable life insurance policyholders by implementing a volatility management strategy in certain portfolios